Abstract:Background: The purpose of this study was to evaluate safety and efficacy of a radiofrequency ablation system in clinical practice. Methods: In 35 patients (age 63,9 +/- 12,6 years, range 22 - 83) a total of 65 liver tumors were percutaneously treated using a 200 watt radiofrequency generator and a LeVeen 4 cm array probe (RF3000, Boston Scientific). The interventions were performed under CT guidance in local anaesthesia and sedation. Adapted to the tumor size, the LeVeen Probe was repositioned during the procedure with an additional safety margin of 1 cm. Primary tumors were colorectal in 22, and mamma tumors (n = 4), zystic pancreas tumors (n = 2), gastric cancer (n = 1), zystadenocarcinoma of the liver (n = 1), lung cancer (n = 1), gastrointestinal stroma tumor (n = 1), duodenal carcinoma (n = 1), cholangiocellular carcinoma (n = 1) and hepatocellular carcinoma (n = 1). Post interventional control and follow-up was performed with multislice-CT (collimation 2.5 mm, unenhanced and contrast enhanced, arterial and portal filling) at 4 weeks, and every three months. Results: One to 4 metastases were treated per patient during one or up to 4 procedure sessions. Mean lesion size was 2,3 +/- 1,2 cm (range 0,2 to 7,0). The corresponding size of the necrosis achieved was 4,6 +/- 1,4 cm (range 2,0 - 8,2). Primary technical success with complete tumor ablation was reached in 60 of 65 lesions. In 4 cases two treatment sessions were necessary in order to achieve the intended results. In one case the procedure was aborted because of a close relationship between lesion and right colon. 63 tumors were treated in sedation and local anesthesia. General anesthesia was necessary in two cases, in one who refused intervention in sedation, and in another case with insufficient analgetic effect. Morbidity was 9.2 %: Bleeding complications (n = 3, one arterial bleeding from the ablation tract, two intrahepatic bleedings with extrahepatic hematoma) were confirmed by selective angiography of the hepatic artery and were treated with coil embolisation of the respective segmental arteries. One case with subcapsular tumor ablation suffered from a large subcapsular hematoma requiring a blood transfusion. In one case with a subphrenic location of the metastasis, the needle electrode had passed the costophrenic recessus and resulted in an hematothorax. This patient was treated by pleural drainage for two days. One patient suffered from fever up to 39 degrees C and inflammation of the biliary tract and received a cholecystectomy 22 days post interventionally. There was no peri interventional mortality. Mean follow-up is 5,6 +/- 3,3 months (range 0 to 13). 21 of 35 patients showed no evidence of tumor recurrence. One case is scheduled for a second treatment session for complete tumor ablation. 13 of 35 patients suffered from tumor recurrence, either local recurrences and/or new metastases. At the sites of prior RF-ablation 9 local recurrences were detected in 7 patients, two cases with isolated local recurrences and 5 cases with local recurrences and new metastases. 6 Patients showed no evidence for local recurrences but new metastases. In these 11 cases a total of 37 metastases were found at new locations. In three patients tumor recurrence was treated by means of a second RF-ablation. The remaining 10 patients received chemotherapy. Conclusion: RF-ablation can be performed in local anaesthesia and sedation with low peri interventional morbidity and mortality. Using the LeVeen probe and a 200 watt generator, appropriate necroses can be achieved. CT follow-up is required every three months because of the tumor recurrence rate and reinterventions may be required.

Treatment of Liver Tumors Using Radiofrequency Ablation with a Multi-Electrode and Multi-Sited Switching System: Efficacy Analysis in 176 Patients

Clinical effectiveness of radiofrequency ablation with a multiple-electrode switching system for liver tumors

[Experience of Radiofrequency Ablation on Liver Malignancies: a Report of 803 Cases].

Treatment Efficacy of Radiofrequency Ablation of 338 Patients with Hepatic Malignant Tumor and the Relevant Complications.

[Efficacy of Radiofrequency Ablation of 343 Patients with Hepatic Tumor and the Relevant Complications].

Treatment Strategy to Optimize Radiofrequency Ablation for Liver Malignancies.

[Percutaneous radiofrequency ablation of liver tumors using the LeVeen 4 cm array probe]

Clinical short-term results of radiofrequency ablation in liver cancers.

Percutaneous Radiofrequency Ablation With a Multiple-Electrode Switching System for Medium-Sized Hepatocellular Carcinomas

Radiofrequency Ablation in Treatment of Malignant Liver Tumors

Multiple-electrode Radiofrequency Ablation Via Switching System in Treating Early-Stage Hepatocellular Carcinoma

Safety and efficacy of No-touch radiofrequency ablation in treating single liver tumor ≤3 cm (a report of 50 cases)

Clinical Short—term Results of Radiofrequency Ablation in L;iver Cancers

Radiofrequency ablation for the treatment of liver malignant tumor:report of 956 cases

[Long Term (5 Years) Outcome of Radiofrequency Ablation for Hepatocellular Carcinoma in 256 Cases].

Multiple-electrode radiofrequency ablation of small hepatocellular carcinomas

Percutaneous Radiofrequency Ablation for Liver Tumors: is It Safer and More Effective in Low-Risk Areas Than in High-Risk Areas?

Ultrasound-guided Radiofrequency Ablation in the Treatment of Hepatic Tumors

Percutaneous Radiofrequency Ablation of Malignant Liver Tumors with Ultrasound and CT Fusion Imaging Guidance.

[The Importance of Image Guided Radiofrequency Ablation with Standard Treatment Strategy for Liver Malignancies].

Ultrasound-guided Radiofrequency Ablation of Malignant Hepatic Tumors